Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia

• Published in: Human gene therapy. Clinical development Vol. 27; no. 1; p. 37
• Main Authors: Ye, Guo-jie, Budzynski, Ewa, Sonnentag, Peter, Nork, T Michael, Miller, Paul E, Sharma, Alok K, Ver Hoeve, James N, Smith, Leia M, Arndt, Tara, Calcedo, Roberto, Gaskin, Chantelle, Robinson, Paulette M, Knop, David R, Hauswirth, William W, Chulay, Jeffrey D
• Format: Journal Article
• Language: English
• Published: United States 01-03-2016
• Subjects: Animals; Color Vision Defects - therapy; Cyclic Nucleotide-Gated Cation Channels - genetics; Cyclic Nucleotide-Gated Cation Channels - metabolism; Dependovirus - genetics; DNA, Recombinant - administration & dosage; DNA, Recombinant - adverse effects; Female; Genetic Therapy; Genetic Vectors - administration & dosage; Genetic Vectors - adverse effects; Humans; Injections, Intraocular; Macaca fascicularis; Male
• ISSN: 2324-8645
• DOI: 10.1089/humc.2015.164

Applied Genetic Technologies Corporation (AGTC) is developing rAAV2tYF-PR1.7-hCNGB3, a recombinant adeno-associated viral (rAAV) vector expressing the human CNGB3 gene, for treatment of achromatopsia, an inherited retinal disorder characterized by markedly reduced visual acuity, extreme light sensitivity, and absence of color discrimination. We report here results of a study evaluating the safety and biodistribution of rAAV2tYF-PR1.7-hCNGB3 in cynomolgus macaques. Three groups of animals (n = 2 males and 2 females per group) received a subretinal injection in one eye of 300 μl containing either vehicle or rAAV2tYF-PR1.7-hCNGB3 at one of two concentrations (4 × 10(11) or 4 × 10(12) vector genomes/ml) and were evaluated over a 3-month period before being euthanized. Administration of rAAV2tYF-PR1.7-hCNGB3 was associated with a dose-related anterior and posterior segment inflammatory response that was greater than that observed in eyes injected with the vehicle control. Most manifestations of inflammation improved over time except that vitreous cells persisted in vector-treated eyes until the end of the study. One animal in the lower vector dose group was euthanized on study day 5, based on a clinical diagnosis of endophthalmitis. There were no test article-related effects on intraocular pressure, visual evoked potential responses, hematology or clinical chemistry parameters, or gross necropsy observations. Histopathological examination demonstrated minimal mononuclear infiltrates in all vector-injected eyes. Serum anti-AAV antibodies developed in all vector-injected animals. No animals developed antibodies to CNGB3. Biodistribution studies demonstrated high levels of vector DNA in the injected eye but minimal or no vector DNA in any other tissue. These results support the use of rAAV2tYF-PR1.7-hCNGB3 in clinical studies in patients with achromatopsia caused by CNGB3 mutations.